European Journal of Neurology

Article	Citations
Amyotrophic lateral sclerosis: a clinical review	438
Acute‐onset smell and taste disorders in the context of COVID‐19: a pilot multicentre polymerase chain reaction based case–control study	226
Does SARS‐Cov‐2 invade the brain? Translational lessons from animal models	192
European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision	146
Neuropsychiatric symptoms and quality of life in Spanish patients with Alzheimer’s disease during the COVID‐19 lockdown	134
Two patients with acute meningoencephalitis concomitant with SARS‐CoV‐2 infection	122
Stroke care during the COVID‐19 pandemic: experience from three large European countries	118
COVID‐19‐related encephalopathy: a case series with brain FDG‐positron‐emission tomography/computed tomography findings	115
Neurological outcome and quality of life 3 months after COVID‐19: A prospective observational cohort study	113
Cognitive decline among individuals with history of mild symptomatic SARS‐CoV‐2 infection: A longitudinal prospective study nested to a population cohort	106
A longitudinal study on α‐synuclein in plasma neuronal exosomes as a biomarker for Parkinson’s disease development and progression	106
Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial	104
Cerebral venous thrombosis and severe acute respiratory syndrome coronavirus‐2 infection: A systematic review and meta‐analysis	102
Monogenic cerebral small‐vessel diseases: diagnosis and therapy. Consensus recommendations of the European Academy of Neurology	101
Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID‐19 and associated with neurological symptoms and disease severity	97
Encephalitis as a neurological complication of COVID‐19: A systematic review and meta‐analysis of incidence, outcomes, and predictors	95
Cytokine release syndrome‐associated encephalopathy in patients with COVID‐19	94
COVID‐19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response	92
Headache as an acute and post‐COVID‐19 symptom in COVID‐19 survivors: A meta‐analysis of the current literature	83
Patterns of smell recovery in 751 patients affected by the COVID‐19 outbreak	82
Post‐SARS‐CoV‐2‐vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency	80
A systematic review of neurological manifestations of SARS‐CoV‐2 infection: the devil is hidden in the details	80
The international European Academy of Neurology survey on neurological symptoms in patients with COVID‐19 infection	78
Prevalence, clinical characteristics and outcomes of Guillain−Barré syndrome spectrum associated with COVID‐19: A systematic review and meta‐analysis	78
Sex and gender differences in Alzheimer’s disease: current challenges and implications for clinical practice	77

Miller‐Fisher syndrome after SARS‐CoV‐2 infection	77
Impact of the COVID‐19 outbreak on acute stroke pathways – insights from the Alsace region in France	76
Neurological autoimmune diseases following vaccinations against SARS‐CoV‐2: a case series	76
Neurological manifestations and neuro‐invasive mechanisms of the severe acute respiratory syndrome coronavirus type 2	72
Emergency room neurology in times of COVID‐19: malignant ischaemic stroke and SARS‐CoV‐2 infection	70
Disability through COVID‐19 pandemic: neurorehabilitation cannot wait	69
Hypoperfusion intensity ratio correlates with angiographic collaterals in acute ischaemic stroke with M1 occlusion	67
European Academy of Neurology guideline on the management of medication‐overuse headache	66
COVID‐19 and herpes zoster co‐infection presenting with trigeminal neuropathy	65
Neuropathological findings from COVID‐19 patients with neurological symptoms argue against a direct brain invasion of SARS‐CoV‐2: A critical systematic review	62
European guideline and expert statements on the management of narcolepsy in adults and children	56
Guillain–Barré syndrome associated with SARS‐CoV‐2 infection. A systematic review	56
Increased risk of acute stroke among patients with severe COVID‐19: a multicenter study and meta‐analysis	54
European Stroke Organisation and European Academy of Neurology joint guidelines on post‐stroke cognitive impairment	54
Neurological outcomes 1 year after COVID‐19 diagnosis: A prospective longitudinal cohort study	53
COVID‐19 and ischemic stroke	53
SARS‐CoV‐2 and Guillain–Barré syndrome: AIDP variant with a favourable outcome	53
One‐year cognitive follow‐up of COVID‐19 hospitalized patients	52
Predictive factors for a severe course of COVID‐19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival	50
A European Academy of Neurology guideline on medical management issues in dementia	48
Miller‐Fisher syndrome after COVID‐19: neurochemical markers as an early sign of nervous system involvement	48
Safety of the BNT162b2 COVID‐19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel	47
Novel coronavirus and the central nervous system	47
Rapid onset of functional tic‐like behaviours in young adults during the COVID‐19 pandemic	47
Early data on long‐term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2‐year update from the open‐label extension of the NEURO‐TTR trial	47
Myopathy as a cause of fatigue in long‐term post‐COVID‐19 symptoms: Evidence of skeletal muscle histopathology	46
Headache during SARS‐CoV‐2 infection as an early symptom associated with a more benign course of disease: a case–control study	44
Subthalamic beta band suppression reflects effective neuromodulation in chronic recordings	44
Severe acute respiratory syndrome coronavirus 2 may be an underappreciated pathogen of the central nervous system	44
Functional motor disorders associated with other neurological diseases: Beyond the boundaries of “organic” neurology	44
Female reproductive factors and the risk of dementia: a nationwide cohort study	43
Guillain‐Barré syndrome in a patient with antibodies against SARS‐COV‐2	43
Minocycline in neurodegenerative and psychiatric diseases: An update	43
EAN/ERS/ESO/ESRS statement on the impact of sleep disorders on risk and outcome of stroke	43
Altered motor cortex physiology and dysexecutive syndrome in patients with fatigue and cognitive difficulties after mild COVID‐19	42
Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3‐month observational, longitudinal, cohort, multicenter, Italian real‐life study	42
COVID‐19 pandemic and mental distress in multiple sclerosis: Implications for clinical management	41
Opinions and clinical practices related to diagnosing and managing functional (psychogenic) movement disorders: changes in the last decade	41
Guillain–Barré syndrome after SARS‐CoV‐2 infection	40
Dysphagia in COVID‐19 –multilevel damage to the swallowing network?	39
Blood–brain barrier leakage and hemorrhagic transformation: The Reperfusion Injury in Ischemic StroKe (RISK) study	39
Unraveling the enigma of new‐onset refractory status epilepticus: a systematic review of aetiologies	39
Olfactory bulb and mucosa abnormalities in persistent COVID‐19‐induced anosmia: a magnetic resonance imaging study	39
Trimethylamine‐N‐oxide is elevated in the acute phase after ischaemic stroke and decreases within the first days	39
Predictive factors of smell recovery in a clinical series of 288 coronavirus disease 2019 patients with olfactory dysfunction	38
Distal hereditary motor neuropathies: Mutation spectrum and genotype–phenotype correlation	38
Clinical characteristics and outcomes of thymoma‐associated myasthenia gravis	38
Non‐motor symptom burden is strongly correlated to motor complications in patients with Parkinson’s disease	37
Myasthenia gravis associated with anti‐MuSK antibodies developed after SARS‐CoV‐2 infection	37
COVID‐19: what if the brain had a role in causing the deaths?	36

Blood biomarkers and prognosis of amyotrophic lateral sclerosis	35
The need for neurologists in the care of COVID‐19 patients	34
Assessment of neurological manifestations in hospitalized patients with COVID‐19	34
Declining mortality of cerebral venous sinus thrombosis with thrombocytopenia after SARS‐CoV‐2 vaccination	34
Colchicine for stroke prevention in patients with coronary artery disease: a systematic review and meta‐analysis	34
International online survey of 1048 individuals with functional neurological disorder	33
Relationship between COVID‐19 and movement disorders: A narrative review	33
Perceived stress and social support in a large population of people with multiple sclerosis recruited online through the COVID‐19 pandemic	33
The European Academy of Neurology Brain Health Strategy: One brain, one life, one approach	33
Treatment with the monoclonal calcitonin gene‐related peptide receptor antibody erenumab: A real‐life study	33
CADASIL: yesterday, today, tomorrow	32
CD8+ T‐cell predominance in autoimmune glial fibrillary acidic protein astrocytopathy	32
Lack of dyspnea in patients with Covid‐19: another neurological conundrum?	32
Cognitive sequelae of long COVID may not be permanent: A prospective study	32
Muscle involvement in SARS‐CoV‐2 infection	32
Bilateral facial nerve palsy associated with COVID‐19 and Epstein–Barr virus co‐infection	32
Automated speech analysis in early untreated Parkinson's disease: Relation to gender and dopaminergic transporter imaging	32
The European Academy of Neurology COVID‐19 registry (ENERGY): an international instrument for surveillance of neurological complications in patients with COVID‐19	31
Neurophysiological investigations of drug resistant epilepsy patients treated with vagus nerve stimulation to differentiate responders from non‐responders	31
Cross‐sectional area reference values for peripheral nerve ultrasound in adults: a systematic review and meta‐analysis—Part I: Upper extremity nerves	31
Hypomimia in Parkinson’s disease: an axial sign responsive to levodopa	31
Low‐dose rescue tirofiban in mechanical thrombectomy for acute cerebral large‐artery occlusion	31
Minor hallucinations reflect early gray matter loss and predict subjective cognitive decline in Parkinson's disease	30
Dysphagia, dysarthria and aphasia following a first acute ischaemic stroke: incidence and associated factors	30
Lee Silverman Voice Treatment for dysarthria in patients with Parkinson’s disease: a systematic review and meta‐analysis	29
Maintenance of response and predictive factors of 1‐year GalcanezumAb treatment in real‐life migraine patients in Italy: The multicenter prospective cohort GARLIT stud	29
Plasma neurofilament light chain as a potential biomarker in Charcot‐Marie‐Tooth disease	29
Epstein–Barr virus infection after adolescence and human herpesvirus 6A as risk factors for multiple sclerosis	29
Systematic review of cases of acute myelitis in individuals with COVID‐19	29
Correlation between total homocysteine and cerebral small vessel disease: A Mendelian randomization study	29
Ischaemic stroke in the time of coronavirus disease 2019	29
COVID‐19 meningitis without pulmonary involvement with positive cerebrospinal fluid PCR	28
Fatigue in multiple sclerosis patients with different clinical phenotypes: a clinical and magnetic resonance imaging study	28
SARS‐CoV‐2–associated Guillain‐Barre syndrome in 62 patients	28
Diagnosis and prevalence of diabetic polyneuropathy: a cross‐sectional study of Danish patients with type 2 diabetes	28
Usability of the head impulse test in routine clinical practice in the emergency department to differentiate vestibular neuritis from stroke	27
Acute cerebellar ataxia and myoclonus with or without opsoclonus: a para‐infectious syndrome associated with COVID‐19	27
Periventricular white matter hyperintensity burden and cognitive impairment in early Parkinson’s disease	27
Inhibitory synapse loss and accumulation of amyloid beta in inhibitory presynaptic terminals in Alzheimer's disease	27
Impact of COVID‐19 outbreak in reperfusion therapies of acute ischaemic stroke in northwest Spain	27
The Framingham cardiovascular risk score and 5‐year progression of multiple sclerosis	27
Concomitant brain arterial and venous thrombosis in a COVID‐19 patient	27
Multiple Sclerosis Performance Test: validation of self‐administered neuroperformance modules	26
Neurological complications of COVID‐19 in hospitalized patients: The registry of a neurology department in the first wave of the pandemic	26
Chronic immunoglobulin maintenance therapy in myasthenia gravis	26
A novel nomogram to predict early neurological deterioration in patients with acute ischaemic stroke	26
Socioeconomic impact of restless legs syndrome and inadequate restless legs syndrome management across European settings	26
Cognitive frailty and falls in Chinese elderly people: a population‐based longitudinal study	26
Using machine learning to predict stroke‐associated pneumonia in Chinese acute ischaemic stroke patients	26
Association between neuropathy and B‐vitamins: A systematic review and meta‐analysis	26
Multiple sclerosis and COVID‐19: How many are at risk?	26
Altered resting‐state functional connectivity between subregions in the thalamus and cortex in migraine without aura	25
Intracranial aneurysm wall enhancement as an indicator of instability: a systematic review and meta‐analysis	25
Risk and outcomes of COVID‐19 in patients with multiple sclerosis	25
Cognitive processing speed in multiple sclerosis clinical practice: association with patient‐reported outcomes, employment and magnetic resonance imaging metrics	25
Clinic and genetic predictors in response to erenumab	25
Cerebrospinal and blood levels of amino acids as potential biomarkers for Parkinson’s disease: review and meta‐analysis	25
Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial	25
Endovascular treatment for basilar artery occlusion: A systematic review and meta‐analysis	25
Optical coherence tomography measurements as potential imaging biomarkers for Parkinson's disease: A systematic review and meta‐analysis	25
Molecular analysis and clinical diversity of distal hereditary motor neuropathy	25
The etiology of rhabdomyolysis: an interaction between genetic susceptibility and external triggers	24
Emerging concepts on bradykinesia in non‐parkinsonian conditions	24
Relationships between retinal layer thickness and brain volumes in the UK Biobank cohort	24
Integrated evaluation of a panel of neurochemical biomarkers to optimize diagnosis and prognosis in amyotrophic lateral sclerosis	24
European Academy of Neurology and European Federation of Neurorehabilitation Societies guideline on pharmacological support in early motor rehabilitation after acute ischaemic stroke	24
Efficacy and safety of rituximab in myasthenia gravis: a French multicentre real‐life study	24
Early shunt surgery improves survival in idiopathic normal pressure hydrocephalus	24
Large vessel occlusion is independently associated with atrial fibrillation detection	24
Functional connectivity and topology in patients with restless legs syndrome: a case–control resting‐state functional magnetic resonance imaging study	24
The long‐term outcome of MOGAD: An observational national cohort study of 61 patients	24
Predictors of sustained response and effects of the discontinuation of anti‐calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine	24
Machine‐learning‐based outcome prediction in stroke patients with middle cerebral artery‐M1 occlusions and early thrombectomy	23
Physical and cognitive profiles in motoric cognitive risk syndrome in an older population from Southern Italy	23
Endovascular therapy versus no endovascular therapy in patients receiving best medical management for acute isolated occlusion of the posterior cerebral artery: A systematic review and meta‐analy	23
Is there evidence of bradykinesia in essential tremor?	23
Non‐invasive and tracheostomy invasive ventilation in amyotrophic lateral sclerosis: Utilization and survival rates in a cohort study over 12 years in Germany	23
Daratumumab for treatment‐refractory antibody‐mediated diseases in neurology	23
Misdiagnosis and diagnostic pitfalls of chronic inflammatory demyelinating polyradiculoneuropathy	23
Nitrous oxide‐induced myeloneuropathy	22

European Academy of Neurology/Movement Disorder Society ‐ European Section guideline on the treatment of Parkinson's disease: I. Invasive therapies	22
Charcot–Marie–Tooth disease misdiagnosed as chronic inflammatory demyelinating polyradiculoneuropathy: An international multicentric retrospective study	22
Tau and neurofilament light‐chain as fluid biomarkers in spinocerebellar ataxia type 3	22
EAN consensus statement for management of patients with neurological diseases during the COVID‐19 pandemic	22
Safety and tolerability of SARS‐Cov‐2 vaccination in patients with myasthenia gravis: A multicenter experience	22
Antiherpetic medication and incident dementia: Observational cohort studies in four countries	22
Meningitis due to cerebrospinal fluid leak after nasal swab testing for COVID‐19	22
Persistent visual dysfunction following posterior reversible encephalopathy syndrome due to COVID‐19: Case series and literature review	22
Healthcare costs of post‐stroke oropharyngeal dysphagia and its complications: malnutrition and respiratory infections	22
Clinical and radiological profile of patients with spinal muscular atrophy type 4	21
Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo‐controlled, dose‐finding trial followed by 24 months of treatment	21
Prognosis and risk factors associated with asymptomatic intracranial hemorrhage after endovascular treatment of large vessel occlusion stroke: a prospective multicenter cohort study	21
Sex differences in acute ischaemic stroke patients: clinical presentation, causes and outcomes	21
Thrombolysis and bridging therapy in patients with acute ischaemic stroke and Covid‐19	21
Inner retinal layer thinning in radiologically isolated syndrome predicts conversion to multiple sclerosis	21
Intravenous thrombolysis for large vessel or distal occlusions presenting with mild stroke severity	21
EAN guideline on palliative care of people with severe, progressive multiple sclerosis	21
KCNN2 mutation in autosomal‐dominant tremulous myoclonus‐dystonia	21
Neurological symptoms and complications in predominantly hospitalized COVID‐19 patients: Results of the European multinational Lean European Open Survey on SARS‐Infected Patients (LEOSS)	21
Risk factors for 2‐year mortality in patients with prolonged disorders of consciousness: An international multicentre study	21
European Neuromuscular Centre consensus statement on anaesthesia in patients with neuromuscular disorders	21
A full year of the COVID‐19 pandemic with two infection waves and its impact on ischemic stroke patient care in Germany	20
Gut microbiota and metabolome distinctive features in Parkinson disease: Focus on levodopa and levodopa‐carbidopa intrajejunal gel	20
Progressive supranuclear palsy often develops idiopathic normal pressure hydrocephalus‐like magnetic resonance imaging features	20
Protective factors for subjective cognitive decline individuals: trajectories and changes in a longitudinal study with Italian elderly	20
Functional neurological disorders presenting as emergencies to secondary care	20
The spectrum of functional tic‐like behaviours: Data from an international registry	20
Worldwide barriers to genetic testing for movement disorders	20
Guillain‐Barré syndrome and COVID‐19: A 1‐year observational multicenter study	20
Cytomegalovirus seropositivity is associated with reduced risk of multiple sclerosis—a presymptomatic case–control study	20
Optical coherence tomography measures correlate with brain and spinal cord atrophy and multiple sclerosis disease‐related disability	20
Early neurological deterioration following thrombolysis for minor stroke with isolated internal carotid artery occlusion	20
Brain volume loss due to donanemab	20
Efficacy and safety of 5‐hydroxytryptophan on depression and apathy in Parkinson's disease: a preliminary finding	20
Association between depression and motoric cognitive risk syndrome among community‐dwelling older adults in China: A 4‐year prospective cohort study	20
Insomnia disorder: clinical and research challenges for the 21st century	20
Speech metrics, general disability, brain imaging and quality of life in multiple sclerosis	19
European Academy of Neurology/European Alzheimer’s Disease Consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairment	19
Antidiabetics, statins and the risk of amyotrophic lateral sclerosis	19
Association of short‐term exposure to ambient air pollution with mortality from ischemic and hemorrhagic stroke	19
Expanding the clinical spectrum of anti‐IgLON5 disease: A multicenter retrospective study	19
European Society for the Study of Tourette Syndrome 2022 criteria for clinical diagnosis of functional tic‐like behaviours: International consensus from experts in tic disorders	19
Reply to letter on Acute‐onset smell and taste disorders in the context of COVID‐19: a pilot multicentre polymerase chain reaction based case–control study	19
Is there a correlation between MOG‐associated disorder and SARS‐CoV‐2 infection?	19
Moyamoya disease in a European setting: a Danish population‐based study	19
Cross‐sectional area reference values for peripheral nerve ultrasound in adults: A systematic review and meta‐analysis—Part II: Lower extremity nerves	19
Headache at onset of first‐ever ischemic stroke: Clinical characteristics and predictors	19
Functional connectivity changes in complex migraine aura: beyond the visual network	19
Influence of age at disease onset on future relapses and disability progression in patients with multiple sclerosis on immunomodulatory treatment	19
Tau protein as a diagnostic and prognostic biomarker in amyotrophic lateral sclerosis	19
Differences in neurology residency training programmes across Europe – a survey among the Residents and Research Fellow Section of the European Academy of Neurology national representatives	19
B‐type natriuretic peptide over N‐terminal pro‐brain natriuretic peptide to predict incident atrial fibrillation after cryptogenic stroke	19
Clinical and genetic features of patients with amyotrophic lateral sclerosis in southern China	19
Neurofilament light chain and total tau in the differential diagnosis and prognostic evaluation of acute and chronic inflammatory polyneuropathies	18
Incidence of motor neuron disease/amyotrophic lateral sclerosis in South Africa: a 4‐year prospective study	18
Predicting atrial fibrillation after cryptogenic stroke via a clinical risk score—a prospective observational study	18
Atrial fibrosis in embolic stroke of undetermined source: A multicenter study	18
Social cognition in cervical dystonia: phenotype and relationship to anxiety and depression	18
Altered ioflupane single‐photon emission computed tomography in anti‐IgLON5 disease: A new case mimicking probable progressive supranuclear palsy and review of the literature	18
The prevalence of hypertension in multiple sclerosis based on 37 million electronic health records from the United States	18
Aggressive multiple sclerosis: a single‐centre, real‐world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab	18
Status epilepticus with prominent motor symptoms clusters into distinct electroclinical phenotypes	18
Non‐alcoholic fatty liver disease and stroke: A Mendelian randomization study	18
Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score	18
Box and block test, hand grip strength and nine‐hole peg test: correlations between three upper limb objective measures in multiple sclerosis	18
Distinct intra‐arterial clot localization affects tissue‐level collaterals and venous outflow profiles	18
Minimal clinically important differences in functional motor scores in adults with spinal muscular atrophy	18
Genotype and phenotype distribution of 435 patients with Charcot–Marie–Tooth disease from central south China	18
Clinical presentation and management strategies of cardiovascular autonomic dysfunction following a COVID‐19 infection – A systematic review	18
The Unruptured Intracranial Aneurysm Treatment Score as a predictor of aneurysm growth or rupture	18
Pioglitazone and statins lower incidence of Parkinson disease in patients with diabetes mellitus	18
Data‐driven machine‐learning analysis of potential embolic sources in embolic stroke of undetermined source	17
Delirium in acute stroke: A prospective, cross‐sectional, cohort study	17
Statins, diabetes mellitus and prognosis of amyotrophic lateral sclerosis: data from 501 patients of a population‐based registry in southwest Germany	17
Effects of exergaming on hippocampal volume and brain‐derived neurotrophic factor levels in Parkinson’s disease	17
Bi‐hemispheric transcranial direct current stimulation for upper‐limb hemiparesis in acute stroke: a randomized, double‐blind, sham‐controlled trial	17
Ischemic stroke in COVID‐19 patients: Mechanisms, treatment, and outcomes in a consecutive Swiss Stroke Registry analysis	17
In‐vivo signatures of neurodegeneration in isolated rapid eye movement sleep behaviour disorder	17
Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary transthyretin amyloidosis	17
The core/penumbra model: implications for acute stroke treatment and patient selection in 2021	17
Facial nerve palsy: an atypical clinical manifestation of COVID‐19 infection in a family cluster	17
Migraine prevalence in visual snow with prior illicit drug use (hallucinogen persisting perception disorder) versus without	17
Bruns' nystagmus revisited: A sign of stroke in patients with the acute vestibular syndrome	17
A multicenter study of transient global amnesia for the better detection of magnetic resonance imaging abnormalities	17
Prevalence and factors associated with motoric cognitive risk syndrome in community‐dwelling older Chinese: a cross‐sectional study	17
Corneal sub‐basal whorl‐like nerve plexus: a landmark for early and follow‐up evaluation in transthyretin familial amyloid polyneuropathy	16
Higher‐quality diet and non‐consumption of meat are associated with less self‐determined disability progression in people with multiple sclerosis: A longitudinal cohort study	16
Unblinded by the light: amyloid‐related imaging abnormalities in Alzheimer’s clinical trials	16
Partial and nonresponders to onabotulinumtoxinA can benefit from anti‐CGRP monoclonal antibodies preventive treatment: A real‐world evidence study	16
Video quality using outpatient smartphone videos in epilepsy: Results from the OSmartViE study	16
Risk of intracranial meningioma with three potent progestogens: A population‐based case–control study	16
Neuronal intranuclear inclusion disease tremor‐dominant subtype: A mimicker of essential tremor	16
Exploratory pilot study of exogenous sustained‐release melatonin on nocturia in Parkinson's disease	16
Cranial nerve involvement in typical and atypical chronic inflammatory demyelinating polyneuropathies	16
Benefit of first‐pass complete reperfusion in thrombectomy is mediated by limited infarct growth	16